Trial Profile
A Study Assessing Safety and Efficacy of Fosaprepitant in Pediatric Patients for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2017
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2017 New trial record
- 02 Jun 2017 Results of preliminary safety assessment (n=20), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.